Document Detail


Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
MedLine Citation:
PMID:  17420198     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: A case of extrapyramidal symptoms (EPS) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented.
SUMMARY: The patient was a 40-year-old male with developmental disabilities. He was nonverbal, profoundly mentally retarded, and diagnosed with obsessive compulsive disorder (OCD) and orthopedic problems. He developed episodic movements possibly consistent with EPS secondary to aripiprazole usage. The patient was antipsychotic naive before initiation of aripiprazole 5 mg daily. Concurrent medications at the time of EPS onset included oxazepam, baclofen, and citalopram. Baclofen and oxazepam were prescribed secondary to right-sided hemiparesis contractures. Aripiprazole, 5 mg daily, was initiated in November 2004 as an augmentation strategy for the diagnosis of OCD. Facial, tongue, and arm movements were first reported approximately five weeks after the initiation of aripiprazole. Initial symptoms resolved after approximately 24 hours. The dosage was increased to 10 mg daily two weeks later. Dystonic episodes continued on an intermittent basis, and the patient presented with lower-lip thrusting and upper-limb athetosis. These movements interfered with the patient's eating, chewing, and holding of utensils. Several of the standard treatment strategies for EPS were used. Initially, diphenhydramine hydrochloride 25 mg was administered orally every six hours. The patient's movements resolved following diphenhydramine administration. Aripiprazole was subsequently discontinued secondary to its lack of efficacy for OCD and the development of a movement disorder.
CONCLUSION: A patient with developmental disabilities who had no history of movement disorders developed EPS following initiation of aripiprazole.
Authors:
Nancy C Brahm; David L McElwain; Robert C Brown
Related Documents :
11566158 - Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania.
1784708 - The ullevål acute ward follow-up study: a personal 7-year follow-up of patients with f...
19359448 - Hippocampal volumes in first-episode psychosis.
24728248 - Is there any relation between anthropometric indices and decrease in seminal parameters?
18630998 - Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease.
17882998 - Epidemiological, clinical and therapeutic features of pediatric kala-azar.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  64     ISSN:  1079-2082     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-10     Completed Date:  2007-06-05     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  827-9     Citation Subset:  IM    
Affiliation:
Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma (UO), Tulsa 74135-2512, USA. nancy-brahm@ouhsc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Algorithms
Antipsychotic Agents / administration & dosage,  adverse effects*
Baclofen
Basal Ganglia Diseases / chemically induced*
Citalopram
Diphenhydramine / therapeutic use
Drug Interactions
Dyskinesia, Drug-Induced*
Humans
Hypnotics and Sedatives / therapeutic use
Male
Mental Disorders / drug therapy*
Oxazepam
Piperazines / administration & dosage,  adverse effects*
Quinolones / administration & dosage,  adverse effects*
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Hypnotics and Sedatives; 0/Piperazines; 0/Quinolones; 1134-47-0/Baclofen; 58-73-1/Diphenhydramine; 59729-33-8/Citalopram; 604-75-1/Oxazepam; 82VFR53I78/aripiprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polymyxin antibiotics for gram-negative infections.
Next Document:  Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis.